Treatment Paradigm in NSCLC Treatment

More documents

Recommendations

Info

Which factors taken to beaccount in NSCLC treatment ?• 1. Staging• 2. ECOGperformance status• 3. Histology
Early stagePotentially resectablediseaseLocally advanced :unresectable diseaseMetastatic disease
Page 5: Early stage (resectable disease)Adj
Page 9 and 10: Stage I,II,III(except IA)
Page 11: Confirm pathologic N2 (if possible)
Page 15 and 16: Which factors taken to beaccount in
Page 17 and 18: First line treatment in NSCLCASCODe
Page 23 and 24: Smoker adeno histologyNon smoker -
Page 25 and 26: Systemic Treatment Options inNSCLC
Page 27 and 28: Does histology matter ...For the se
Page 30: Smoker adeno histologyNon smoker -
Page 33 and 34: CONSORT: EfficacySurvivalMedian OS,
Page 35 and 36: EGFR expression in NSCLCxxxx
Page 37 and 38: Bevacizumab plus TCarb in non-squam
Page 39 and 40: EGFR expression in NSCLCEGFR TKIsxx
Page 45 and 46: Role of EGFR-TKIs in NSCLCClinical
Page 47 and 48: Mutations in EGFR TK inUnselected P
Page 49: At least 2 positive clinical factor
Page 54 and 55:
Overall survival (ITT population)Ge
Page 56 and 57:
EURTAC: First-line Erlotinib vs Che
Page 58 and 59:
ASCO : RecommendationsECOG 0-1 :1 s
Page 60 and 61:
2004: pemetrexed versus docetaxel -
Page 62:
Second line treatment in Advanced N
Page 65 and 66:
Summary of available clinical evide
Page 67 and 68:
Maintenance Pemetrexed : DFSBenefit
Page 69 and 70:
1st Line
Page 71 and 72:
1st Line2nd Line Docetaxel Docetaxe
show all

Treatment Paradigm in NSCLC Treatment

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?